

RealRate

PHARMACEUTICAL 2021











PHARMACEUTICAL 2021



RealRate

Lantern Pharma Inc. Rank 33 of 402

The relative strengths and weaknesses of Lantern Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lantern Pharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 80% points. The greatest weakness of Lantern Pharma Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 266%, being 219% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	20,237
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	552
Liabilities, Non-Current	0
Other Assets	101
Other Compr. Net Income	0
Other Expenses	2,243
Other Liabilities	108
Other Net Income	0
Other Revenues	0
Property and Equipment	22
Research and Development	0
Selling, General and Administrative Expense	3,665

Output Variable	Value in 1000 USD
Assets	20,360
Liabilities	661
Expenses	5,908
Revenues	0
Stockholders Equity	19,699
Net Income	-5,908
Comprehensive Net Income	-5,908
Economic Capital Ratio	266%

